Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 229

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Long‐term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes

Bode, B., Stenlöf, K., Harris, S., Sullivan, D., Fung, A., Usiskin, K., Meininger, G.·2015·Diabetes, Obesity and Metabolism

Abstract

Aims: The long‐term efficacy and safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, was evaluated over 104 weeks in patients aged 55–80 years with type 2 diabetes mellitus ( T2DM ) inadequately controlled on a stable antihyperglycaemic agent regimen. Methods: In this randomized, double‐blind, phase III study, patients received canagliflozin 100 or 300 mg or placebo once daily during a 26‐week core period (N = 714) and a 78‐week extension period (n = 624). Efficacy endpoints at week 104 included change from baseline in glycated haemoglobin ( HbA1c ), fasting plasma glucose ( FPG ) and systolic blood pressure, and percent change from baseline in body weight and fasting plasma lipids. Safety was assessed by adverse event ( AE ) reports. Results: At week 104, canagliflozin 100 and 300 mg were associated with reductions in HbA1c versus placebo (−0.32 and −0.43% vs 0.17%, respectively; overall mean baseline, 7.7%) and more patients achieved HbA1c <7.0% with canagliflozin 100 and 300 mg than with placebo (35.8 and 41.9% vs 20.3%, respectively). Reductions in FPG , body weight and systolic blood pressure, and increases in high‐density lipoprotein cholesterol (HDL‐C) and low‐density lipoprotein cholesterol (LDL‐C) were seen with canagliflozin compared with placebo. The overall incidence rates of AEs over 104 weeks were 88.0, 89.8 and 86.1% with canagliflozin 100 and 300 mg and placebo, respectively; serious AE rates were low across treatment groups. The incidence rates of urinary tract infections, genital mycotic infections and osmotic diuresis– and volume depletion–related AEs were higher with canagliflozin than with placebo. Conclusion: Canagliflozin improved glycaemic control, reduced body weight and systolic blood pressure, and was generally well tolerated in patients aged 55–80 years with T2DM over 104 weeks.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/dom.12428

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 229

Metadata

Authors
Bode, B., Stenlöf, K., Harris, S., Sullivan, D., Fung, A., Usiskin, K., & Meininger, G.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2015-01-12
Volume
17
Issue
3
Pages
294-303
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2031730303
Cited by
229
References
2
FWCI
21.30
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long‐term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. https://app.cochat.ai/papers/10.1111/dom.12428
The paper
Bode, B., Stenlöf, K., Harris, S., Sullivan, D., Fung, A., Usiskin, K., & Meininger, G. (2015). Long‐term efficacy and safety of canagliflozin over 104 weeks in patients aged 55–80 years with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12428

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.